# US 2024/0002839 A1 · Crispr sam biosensor cell lines and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002839 A1
- Document ID: US20240002839A1
- Status: Published application
- Kind: A1
- Application number: 18/039,937
- Filed: 2021-12-02
- Published: 2024-01-04
- Earliest claimed: 2020-12-02
- Assignees: Decibel Therapeutics, Inc.
- Applicants: Decibel Therapeutics, Inc.
- Inventors: Meghan DRUMMOND SAMUELSON; Leah SABIN; Sarah CANCELARICH
- Web page: https://patentgrep.com/patent/US20240002839A1

## CPC

- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12Q 1/6897: involving reporter genes operably linked to promoters
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed are cell lines that stably express CRISPR SAM complex which comprise a gRNA that specifically targets a promoter of a gene, wherein the gene is not normally expressed in said cell. Also disclosed are methods of measuring the ability of a vector to transfer a nucleic acid molecule into such cell lines.

## Claims

### Claim 1

A cell that stably expresses a CRISPR/Cas9 Synergistic Activation Mediator complex (“CRISPR SAM complex”), wherein the CRISPR complex comprises a gRNA that specifically targets a promoter of a gene and wherein the gene is not normally expressed in said cell.

### Claim 2 (depends on 1)

The cell of claim 1, wherein the CRISPR SAM complex comprises dCas9 or a derivative thereof, wherein the dCas9 or the derivative thereof has a nuclease activity that is eliminated or reduced by at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% compared to a wild type Cas protein.

### Claim 3 (depends on 2)

The cell of claim 2, wherein the Cas protein or the derivative thereof with reduced or eliminated nuclease activity is fused to one or more transcriptional activation domains.

### Claim 4 (depends on 1)

The cell of claim 1, wherein all transcription activation domains in the CRISPR SAM complex are different from each other.

### Claim 5 (depends on 2)

The cell of claim 2, wherein the Cas protein or the derivative thereof with reduced or eliminated nuclease activity is a Cas9-VP64 fusion protein.

### Claim 6 (depends on 1)

The cell of claim 1, wherein said gRNA is an sgRNA.

### Claim 7 (depends on 6)

The cell of claim 6, wherein the sgRNA comprises two MS2 RNA aptamers.

### Claim 8 (depends on 1)

The cell of claim 1, wherein the cell is a mammalian cell

### Claim 9 (depends on 8)

The cell of claim 8, wherein the cell is a human cell.

### Claim 10 (depends on 9)

The cell of claim 9, wherein the cell is an HEK293 cell.

### Claim 11 (depends on 1)

The cell of claim 1, wherein said promoter is a Myo15 promoter.

### Claim 12 (depends on 11)

The cell of claim 11, wherein said promoter is a mouse Myo (mMyo15) promoter.

### Claim 13 (depends on 12)

The cell of claim 12, wherein said gRNA comprises a nucleic acid sequence of CACAGGGGGACAUCAUCUAC (SEQ ID NO: 77).

### Claim 14 (depends on 12)

The cell of claim 12, wherein said gRNA comprises a nucleic acid sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to CACAGGGGGACAUCAUCUAC (SEQ ID NO: 77).

### Claim 15 (depends on 1)

The cell of claim 1, wherein said gRNA specifically targets a promoter that drives expression in liver sinusoidal endothelial cells (LSEC).

### Claim 16

An HK231 cell line that stably expresses a CRISPR/Cas9 Synergistic Activation Mediator complex (“CRISPR SAM complex”), wherein the CRISPR SAM complex comprises a gRNA that specifically targets mMyo15 promoter, wherein:
a) the CRISPR SAM complex comprises a Cas9-VP64 fusion protein, wherein the Cas9-VP64 fusion protein has an eliminated nuclease activity; and
b) the gRNA comprises a nucleic acid sequence of CACAGGGGGACAUCAUCUAC (SEQ ID NO: 77).

### Claim 17

A gRNA sequence comprising a nucleic acid sequence of CACAGGGGGACAUCAUCUAC (SEQ ID NO: 77).

### Claim 18

A gRNA sequence comprising a nucleic acid sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to CACAGGGGGACAUCAUCUAC (SEQ ID NO: 77).

### Claim 19

A gRNA sequence of CACAGGGGGACAUCAUCUAC (SEQ ID NO: 77).

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method of measuring the ability of a vector to transfer a nucleic acid molecule into a cell comprising:
a) introducing the nucleic acid molecule using the vector into the cell of any of claims 1-10, wherein the nucleic acid molecule encodes a gene or a fragment thereof operably linked to a promoter that binds the gRNA expressed by the cell; and
b) measuring the expression of the gene.

### Claim 21 (depends on 20)

The method of claim 20, wherein the vector is a virus.

### Claim 22 (depends on 21)

The method of claim 21, wherein the virus is an AAV virus.

### Claim 23 (depends on 21)

The method of claim 21, wherein the virus is a retrovirus.

### Claim 24 (depends on 21)

The method of claim 21, wherein the virus is a lentivirus.

### Claim 25 (depends on 21)

The method of claim 21, wherein the virus is an adenovirus.

### Claim 26 (depends on 20)

The method of claim 20, wherein the vector is a lipid nanoparticle.

### Claim 27 (depends on 20)

The method of claim 20, wherein the gene is a reporter gene.

### Claim 28 (depends on 27)

The method of claim 27, wherein the reporter gene is selected from the group consisting of: genes encoding beta-galactosidase (lacZ), the bacterial chloramphenicol acetyltransferase (cat) genes, firefly luciferase genes, genes encoding beta-glucuronidase (GUS), and genes encoding fluorescent proteins

### Claim 29 (depends on 27)

The method of claim 27, wherein the reporter gene is an enhanced green fluorescent protein (EGFP).

### Claim 30 (depends on 20)

The method of claim 20, wherein the gene is OTOF.

### Claim 31 (depends on 20)

The method of claim 20, wherein the gene is introduced by more than one vector.

### Claim 32 (depends on 31)

The method of claim 31, wherein the gene is introduced by two vectors.
